Ropes & Gray advised Novo Nordisk in an exclusive license agreement with China-based United Laboratories International Holdings Limited and its wholly-owned subsidiary United Bio-Technology (Hengqin) Co. Ltd. for the rights to United Biotechnology’s UBT251, a drug in clinical development for the treatment of Type 2 diabetes, obesity and other diseases. The transaction was announced on March 24.
Under the license agreement, United Biotechnology will retain the rights for UBT251 in the Chinese mainland, Hong Kong, Macau and Taiwan. Novo Nordisk will be granted exclusive rights to develop, manufacture and commercialize the drug elsewhere. United Biotechnology is eligible to receive an upfront payment of $200 million and potential milestone payments up to $1.8 billion from Novo Nordisk, as well as tiered royalties on net sales outside of the retained territories.
The Ropes & Gray team included life sciences licensing partner Hannah England and life sciences licensing associate Ryan Kramer.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.